news, journals and articles from all over the world.
Embargoed press materials are now available for the virtual Experimental Biology (EB) 2021 meeting, featuring cutting-edge multidisciplinary research from across the life sciences. EB 2021, to be held April 27–30, is the annual meeting of five scientific societies bringing together thousands of scientists and 25 guest societies in one interdisciplinary community.
Read moreEB 2021 will feature the latest insights into COVID-19, cancer, heart disease and more
Read moreThe May 2021 Issue of Diseases of the Colon and Rectum is out! Find out what’s new
Read moreDo you know cancer when you see it? Not everything you think may be cancer on final pathology. Read more
Read moreA new, urine-based test for aggressive prostate cancer being developed at the University of Michigan uses next-generation sequencing to assess 15 biomarkers to find cancer that can be missed by biopsies or imaging tests.
Read moreIn a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumor DNA damage response.
Read moreIn a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL).
Read moreTwo studies led by Baylor College of Medicine shed new light on the unanswered question of why estrogen receptor-positive (ER+)
Read moreResearchers at Baylor College of Medicine and collaborators at other institutions have discovered that POT1, a gene known to be
Read moreTwo new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.
Read moreTwo University of Colorado Cancer Center researchers have received a five-year R01 Award for $497,893 per year from the National Institutes of Health (NIH) to study a potential new drug treatment for salivary gland cancer. The award is part of an inter-campus collaboration between Antonio Jimeno, MD, PhD, co-leader of the Developmental Therapeutics Program, and Tin Tin Su, PhD, co-leader of the Molecular and Cellular Oncology Program.
Read moreUnderstanding the components that control cell division is fundamental to understanding how life works and how alterations in this delicate
Read moreThree teams receive awards from the Dartmouth Innovations Accelerator for Cancer
Read moreScientists have discovered a molecular pathway that counteracts the ability of some viruses to evade the immune response. The findings raise hope in generating better immune responses to viral infections, such as COVID-19, as well as to cancer.
Read moreNew study designed to address health care fragmentation identifies risk factors for readmission to a different hospital from where pancreatic, liver, or stomach cancer operations were initially performed
Read moreTriple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a high fatality rate. Currently, chemotherapy is the
Read moreA growing body of research shows that inhibiting neuropilin-1 activity can slow tumor progression in several types of cancers
Read moreStrategy focuses on reprogramming tissues surrounding the tumor to help the body’s immune system attack the cancer
Read moreHigh expression levels of the gene TRIM63 can serve as an accurate and sensitive biomarker of a subtype of kidney cancer known as microphthalmia-associated transcription factor family aberration-associated renal cell carcinomas — or MiTF renal cell carcinoma.
It’s important to distinguish MiTF from other subtypes of kidney cancers — clear cell, papillary and chromophobe — because these tumors may not respond well to standard, front-line treatments and may respond better to other approaches.
Read moreThe National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and cedazuridine (100 mg).
Read moreResearch by Australian scientists could pave the way to a new treatment for a currently incurable brain cancer in children called Diffuse Intrinsic Pontine Glioma, or DIPG
Read moreJames P. Allison, PhD, Carl H. June, MD and Siddhartha Mukherjee, MD Keynote April 29 Summit
Read moreThe enzyme mTORC2 has been an enigmatic regulator of other enzymes (kinases) such as Protein Kinase C (PKC) and Akt. Now
Read moreLudwig Cancer Research is proud to announce on its 50th anniversary the launch of the newest Branch of the Ludwig Institute for Cancer Research.
Read moreDurham, NC – When leukemia strikes an older person, it is in part due to the aging of his or
Read moreHuman non-alcoholic fatty liver disease (NAFLD) is a little-understood condition that significantly increases the risk of inflammation, fibrosis and liver
Read moreDNA supercoiling is an important contributor to the control of gene expression, and not just collateral damage that cells have to solve
Read moreNew research led by the Garvan Institute of Medical Research has revealed how breast cancer cells that develop during or
Read moreAccounting for approximately four percent of all cancers nationwide according to the National Cancer Institute, head and neck cancer is the term used to describe a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses and mouth. Even though these cancers are not as prevalent as others, everyone should be aware of risk factors and symptoms.
Read moreGlioblastomas are the most common and most aggressive brain tumours. Their survival rate has barely increased over the last 50
Read moreATLANTA – APRIL 12, 2021 – New study finds higher medical financial hardship in adult survivors of adolescent and young
Read moreResearchers decode the recent statistics of the changing profiles of cancer incidence and mortality worldwide and in China to tailor control measures
Read moreScientists, medical researchers at Case Western Reserve, NYU Langone Health and University Hospitals using machine-learning to predict response to immunotherapy
Read moreAn international team today reports the findings of an independent assessment of five commercially-available assays for tumour DNA sequencing –
Read moreDana-Farber researchers find patients whose tumors have low aneuploidy levels often have better outcomes following treatment with immune checkpoint inhibitors
Read moreEarly results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were not able to have their tumors surgically removed.
Read moreRacial and ethnic minority groups, low income, underinsured, or uninsured individuals as well as those living in rural areas, often face greater obstacles when it comes to preventing, treating and surviving cancer.
Read moreSurprising role for so-called “jumping” genes that are a source of genetic mutations responsible for a number of human diseases.
Read moreDetecting and analyzing breast cancer goes beyond the initial discovery of the cancer itself. If a patient has a tumor
Read moreMutations in the DNA of the cell’s energy ‘factories’ increases the chances of survival for people with bowel cancer, according
Read more
Valley-Mount Sinai Comprehensive Cancer Care — part of Ridgewood, NJ, based Valley Health System — is now using new technology to improve the precision of radiation therapy by accounting for the continual motion of a patient’s anatomy so treatment is delivered with greater accuracy and effectiveness.
Valley is the only hospital on the east coast and, only fourth in the nation, using the latest generation of capabilities available in the newest iteration of ExacTrac Dynamic from Brainlab.
Read moreWASHINGTON, April 7, 2021 — On the surface, Parkinson’s disease — a neurodegenerative disorder — and melanoma — a type
Read more
A $15 million gift to Harvard Medical School from the Bertarelli Foundation is boosting efforts to understand and combat rare cancers. Nine teams across the school and its affiliated hospitals describe their efforts to illuminate understudied malignancies.
Read moreThe study is published in ‘Nature Structural & Molecular Biology’
Read moreEvery day, nearly 400 new cases of cancer are diagnosed in Australia. As a major cause of illness and a leading cause of death, many of us, sadly, also know someone with cancer.
Read more
New Treatments Expand Options for Patients with Persistent Cancers
Read more
In a new study, Yale Cancer Center researchers have defined the genetic landscape of uterine leiomyosarcomas (uLMS).
Read moreA new study examines the recent literature on carbon nanotubes toxicity highlighting their strong inflammatory potential for the respiratory system.
Read moreAccording to the American Cancer Society, a noninvasive breast cancer called ductal carcinoma in situ (DCIS) accounts for approximately one of every four new breast cancer cases in the United States. If left untreated, DCIS has the potential to evolve into invasive cancer, so many patients choose to have breast-conserving surgery or mastectomy after a diagnosis.
Read moreA team led by scientists at the Perelman School of Medicine at the University of Pennsylvania has illuminated the functions of mysterious structures in cells called “nuclear speckles,” showing that they can work in partnership with a key protein to enhance the activities of specific sets of genes.
Read more